Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.






Home » Drug Information » FDA-Approved Drugs » 1997
Medical Areas: Cardiology/Vascular Diseases

View By: Year Company Therapeutic Areas Drug Names 

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: Pentoxifylline

Company: Faulding, Mylan Laboratories
Approval Status: Approved July 1997
Treatment Area: chronic occlusive arterial disease

General Information

Pentoxifylline is a 400 mg extended release tablet and the generic equivalent of Trental. It is being marketed by Hoechst Marion Roussel. Pentoxifylline extended release tablets are indicated for the treatment of leg pain caused chronic occlusive arterial disease of the limbs. Patient walking distance and daily activities are limited by the disease. Both Faulding and Mylan are now manufacturing Pentoxifylline.

Clinical Results

In a comparison between aspirin and pentoxifylline in the elderly, the level of pain did not change significantly with either aspirin or pentoxifylline, but patient’s walking distance was extended with the pentoxifylline group.

Mechanism of Action

Pentoxifylline increases red blood cell flexibility and improves blood flow.


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.